Sungrow Unveils Next-Generation Residential ESS Designed for Reliable Backup Power

PHU QUOC, Vietnam, July 23, 2025 /PRNewswire/ -- Sungrow, the global leading PV inverter and energy storage system provider, successfully unveils its next-generation residential energy storage system (ESS) at 2025 Southeast Asia Distribution Summit. Featuring the upgraded MG Series inverters, this new solution covers power ranges from 5 kW to 10 kW. With industry-leading features like full-power operation at 45 °C, active PID recovery, and seamless backup power switching within 4ms, this new solution ensures households stay powered even in extreme climates or unstable grid conditions, designed to meet the rising demand for household energy independence across the region.

MG5/6RL inverters are already available and compatible with over 50 third-party energy storage batteries*. MG8/10RL models and the matching MGL060 battery will be released in Q4 2025.

One System, Endless Lifestyles

• Start Small, Dream Big: The system scales effortlessly from 5kW to 80kW with support for up to eight units in parallel—making it ideal for everything from compact apartments to spacious villas or future expansions. It's also compatible with mainstream third-party batteries, offering the flexibility to meet a wide range of application scenarios.
• Power Your Home, Your Way: Whether starting with solar today or planning for backup power tomorrow, the system adapts as your needs evolve—from PV-only setups to fully off-grid solutions. It also supports versatile configurations, including "Battery Ready" (install the inverter now and add batteries later) and "Backup Only" (a hybrid system without PV panels, offering reliable power during outages).
• One Port, Triple Functionality: Simplify your energy management with one port designed for three smart applications: Graded Load Management, Diesel Generator Coordination, and PV Expansion. Flexible and efficient, it brings intelligent control to any energy scenario.

Robust Backup for Uninterrupted Power

• Seamless Transition, Continuous Comfort: In the event of a grid outage, the hybrid inverter automatically switches to off-grid mode within just 4 milliseconds—ensuring uninterrupted power without light flicker or appliance shutdown. Your daily life stays smooth, even when the grid doesn't.
• Compact Size, Exceptional Power: Despite its small footprint, the system delivers up to 200% overload output for 10 seconds. For example, the MG6RL model can supply 12kW to instantly support high-power appliances like air conditioners, laundry machine during blackouts—making it both reliable and powerful.
• Whisper-Quiet Operation: With noise levels as low as 35 dB—quieter than a library—Sungrow's Immersive Silence technology ensures a peaceful home environment.

Robust Power Generation for Unstoppable Performance

• Double the Punch, Zero Compromise: With up to 200% DC input and 160% maximum output capacity, the system delivers outstanding performance. For example, a 6kW inverter can simultaneously provide 6kW of rated AC output while charging the battery with 3.6kW of DC power—ensuring maximum energy utilization without compromise.
• Compatible with diverse PV Panel: Engineered to support up to 20A input current, the system is compatible with virtually all PV modules on the market. No DC energy goes to waste—enabling greater efficiency and seamless integration with your existing or future solar setup.
• Heat-Defying Performance: Built for extreme conditions, the system maintains full power output even at 45 °C ambient temperature. It ensures stable generation during peak heat hours, boosts self-consumption, and conserves battery power for when it's truly needed—delivering reliability when it matters most.
• Grid-Connected PID Repair, 25 Years of Peak Performance: Featuring Sungrow's patented PID ZERO® technology, the system is the industry's first to actively recover from PID effects without disconnecting from the grid. It counteracts long-term power loss caused by heat and humidity—ensuring your PV modules stay efficient for 25 years, no extra hardware or rewiring required.

Smarter Energy, Seamless Control

• Touch & Monitor at Your Finger: The intuitive 4.3-inch full-color touchscreen offers real-time monitoring and complete local control. Commissioning takes less than 30 seconds—no internet required, as easy as making tea. Dual LED indicators allow quick system checks at a glance: the left shows system status, while the right displays battery state of charge (SOC).
• Storm-Ready in One Tap: Prepare for extreme weather or scheduled outages with a single click—activate fast battery charging from the grid and go from 30% to 100% SOC in just one hour (based on a 6kW/6kWh system), giving you peace of mind when it matters most.
• AI Smart Energy Management: Later integration with Sungrow's iHomeManager (the forecast-based energy management system) will use AI to tailor energy strategies based on usage patterns, weather forecasts, dynamic electricity tariff, and extreme weather alerts, optimizing energy dispatch and boosting household green energy benefits by more than 12%*.

Coming Soon: Longer Lasting, Safer, More Flexible Batteries

Launching in Q4, the new MGL060 battery features large-capacity 314 Ah LFP cells with 8000 cycles (EOL 60%), delivering triple the lifespan of average industry offerings. Its pack-level DC/DC energy optimization works like a dedicated optimizer for each cell group, ensuring each operates independently and efficiently, even when new and old batteries are mixed.

*Notes: Data based on households configured with PV–ESS–EV charging system and heat pumps; actual benefits may vary depending on load types and capacity.

About Sungrow

Sungrow, a global leader in renewable energy technology, has pioneered sustainable power solutions for over 28 years. As of December 2024, Sungrow has installed 740 GW of power electronic converters worldwide. The Company is recognized as the world's No. 1 on PV inverter shipments (S&P Global Commodity Insights) and the world's most bankable energy storage company (BloombergNEF). Its innovations power clean energy projects across the globe, supported by a network of 520 service outlets guaranteeing excellent customer experience. At Sungrow, we're committed to bridging to a sustainable future through cutting-edge technology and unparalleled service. For more information, please visit: www.sungrowpower.com

Media Contact: 
Tianjiao Rong
rongtianjiao@sungrowpower.com 

PHU QUOC, Vietnam, July 23, 2025 /PRNewswire/ -- Sungrow, the global leading PV inverter and energy storage system provider, successfully unveils its next-generation residential energy storage system (ESS) at 2025 Southeast Asia Distribution Summit. Featuring the upgraded MG Series inverters, this new solution covers power ranges from 5 kW to 10 kW. With industry-leading features like full-power operation at 45 °C, active PID recovery, and seamless backup power switching within 4ms, this new solution ensures households stay powered even in extreme climates or unstable grid conditions, designed to meet the rising demand for household energy independence across the region.

MG5/6RL inverters are already available and compatible with over 50 third-party energy storage batteries*. MG8/10RL models and the matching MGL060 battery will be released in Q4 2025.

One System, Endless Lifestyles

• Start Small, Dream Big: The system scales effortlessly from 5kW to 80kW with support for up to eight units in parallel—making it ideal for everything from compact apartments to spacious villas or future expansions. It's also compatible with mainstream third-party batteries, offering the flexibility to meet a wide range of application scenarios.
• Power Your Home, Your Way: Whether starting with solar today or planning for backup power tomorrow, the system adapts as your needs evolve—from PV-only setups to fully off-grid solutions. It also supports versatile configurations, including "Battery Ready" (install the inverter now and add batteries later) and "Backup Only" (a hybrid system without PV panels, offering reliable power during outages).
• One Port, Triple Functionality: Simplify your energy management with one port designed for three smart applications: Graded Load Management, Diesel Generator Coordination, and PV Expansion. Flexible and efficient, it brings intelligent control to any energy scenario.

Robust Backup for Uninterrupted Power

• Seamless Transition, Continuous Comfort: In the event of a grid outage, the hybrid inverter automatically switches to off-grid mode within just 4 milliseconds—ensuring uninterrupted power without light flicker or appliance shutdown. Your daily life stays smooth, even when the grid doesn't.
• Compact Size, Exceptional Power: Despite its small footprint, the system delivers up to 200% overload output for 10 seconds. For example, the MG6RL model can supply 12kW to instantly support high-power appliances like air conditioners, laundry machine during blackouts—making it both reliable and powerful.
• Whisper-Quiet Operation: With noise levels as low as 35 dB—quieter than a library—Sungrow's Immersive Silence technology ensures a peaceful home environment.

Robust Power Generation for Unstoppable Performance

• Double the Punch, Zero Compromise: With up to 200% DC input and 160% maximum output capacity, the system delivers outstanding performance. For example, a 6kW inverter can simultaneously provide 6kW of rated AC output while charging the battery with 3.6kW of DC power—ensuring maximum energy utilization without compromise.
• Compatible with diverse PV Panel: Engineered to support up to 20A input current, the system is compatible with virtually all PV modules on the market. No DC energy goes to waste—enabling greater efficiency and seamless integration with your existing or future solar setup.
• Heat-Defying Performance: Built for extreme conditions, the system maintains full power output even at 45 °C ambient temperature. It ensures stable generation during peak heat hours, boosts self-consumption, and conserves battery power for when it's truly needed—delivering reliability when it matters most.
• Grid-Connected PID Repair, 25 Years of Peak Performance: Featuring Sungrow's patented PID ZERO® technology, the system is the industry's first to actively recover from PID effects without disconnecting from the grid. It counteracts long-term power loss caused by heat and humidity—ensuring your PV modules stay efficient for 25 years, no extra hardware or rewiring required.

Smarter Energy, Seamless Control

• Touch & Monitor at Your Finger: The intuitive 4.3-inch full-color touchscreen offers real-time monitoring and complete local control. Commissioning takes less than 30 seconds—no internet required, as easy as making tea. Dual LED indicators allow quick system checks at a glance: the left shows system status, while the right displays battery state of charge (SOC).
• Storm-Ready in One Tap: Prepare for extreme weather or scheduled outages with a single click—activate fast battery charging from the grid and go from 30% to 100% SOC in just one hour (based on a 6kW/6kWh system), giving you peace of mind when it matters most.
• AI Smart Energy Management: Later integration with Sungrow's iHomeManager (the forecast-based energy management system) will use AI to tailor energy strategies based on usage patterns, weather forecasts, dynamic electricity tariff, and extreme weather alerts, optimizing energy dispatch and boosting household green energy benefits by more than 12%*.

Coming Soon: Longer Lasting, Safer, More Flexible Batteries

Launching in Q4, the new MGL060 battery features large-capacity 314 Ah LFP cells with 8000 cycles (EOL 60%), delivering triple the lifespan of average industry offerings. Its pack-level DC/DC energy optimization works like a dedicated optimizer for each cell group, ensuring each operates independently and efficiently, even when new and old batteries are mixed.

*Notes: Data based on households configured with PV–ESS–EV charging system and heat pumps; actual benefits may vary depending on load types and capacity.

About Sungrow

Sungrow, a global leader in renewable energy technology, has pioneered sustainable power solutions for over 28 years. As of December 2024, Sungrow has installed 740 GW of power electronic converters worldwide. The Company is recognized as the world's No. 1 on PV inverter shipments (S&P Global Commodity Insights) and the world's most bankable energy storage company (BloombergNEF). Its innovations power clean energy projects across the globe, supported by a network of 520 service outlets guaranteeing excellent customer experience. At Sungrow, we're committed to bridging to a sustainable future through cutting-edge technology and unparalleled service. For more information, please visit: www.sungrowpower.com

Media Contact: 
Tianjiao Rong
rongtianjiao@sungrowpower.com 

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Sungrow Unveils Next-Generation Residential ESS Designed for Reliable Backup Power

HIGHLIGHTS

• Following an interim data review of the Cohort Expansion Phase (Phase II) of the SECuRE trial, the Safety Review Committee (SRC) confirms the trial will continue with no modifications to the protocol.

Patient population

• With the SECuRE trial continuing to recruit, a total of nine participants who had evaluable data by the 25^th of November 2025 were included in the interim assessment by the SRC, with the majority of participants receiving at least two cycles of 8 GBq of ⁶⁷Cu-SAR-bisPSMA each by the data cut-off date.
• Seven participants received ⁶⁷Cu-SAR-bisPSMA and two participants were treated with a combination of ⁶⁷Cu-SAR-bisPSMA with enzalutamide.
• Most participants were heavily pre-treated (with 55.6% having received more than 5 previous anti-cancer regimens) and had bone metastasis (66.7%).

Safety

• The safety profile of ⁶⁷Cu-SAR-bisPSMA remains favourable with most related adverse events (AEs) in the Cohort Expansion to date being Grade 1 or 2. The most common AEs were nausea and lymphopenia (observed in 33.3% of participants, for each AE).

Efficacy

• Six participants had at least two prostate specific antigen (PSA) results following ⁶⁷Cu-SAR-bisPSMA administration, with all showing a decrease in PSA. Of those, four participants (66.7%) thus far had a reduction of more than 50% in PSA (PSA50) and two participants (33.3%) had a reduction of more than 80% (PSA80).
• One participant who presented with bone metastasis at enrolment achieved undetectable PSA with no prostate cancer detected by computed tomography (CT) or bone scan following ⁶⁷Cu-SAR-bisPSMA treatment. The participant reported having excellent quality of life following the treatment.

Next Steps

• The SECuRE trial will continue enrolment into the Cohort Expansion Phase with planned completion of recruitment in 2026. Phase III registrational trial planning ongoing based on data generated to date.

SYDNEY, Jan. 15, 2026 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to share a number of updates on the SECuRE trial following an SRC meeting. The SRC has recommended that the trial continue with the Cohort Expansion Phase (Phase II) as planned with no modifications to the protocol. The interim results assessed by the SRC were collected from nine participants enrolled in the cohort that had evaluable data by the cut-off date of the 25^th of November 2025 and continue to show promising efficacy and a favourable safety profile of ⁶⁷Cu-SAR-bisPSMA.

The majority of the nine participants had bone metastasis at enrolment (66.7%) and received multiple lines of previous treatments (more than 5 previous anti-cancer regimens, 55.6%). Median PSA prior to ⁶⁷Cu-SAR-bisPSMA treatment was 18.9 ng/mL (range 1.5-30.2 ng/mL). Six out of these nine participants received at least 2 cycles of 8 GBq of ⁶⁷Cu-SAR-bisPSMA each, with two of them also receiving concomitant enzalutamide.

Of the nine participants included in this SRC analysis, six had at least two PSA results following their ⁶⁷Cu-SAR-bisPSMA treatment by the data cut-off date. Of these six participants, thus far four (66.7%) showed reductions in PSA of 50% or more (PSA50) and two (33.3%) showed reductions of 80% or more (PSA80).

The safety profile of ⁶⁷Cu-SAR-bisPSMA remains favourable in the Cohort Expansion, with the majority of related AEs being Grade 1 or 2. The most common related AEs were nausea and lymphopenia (observed in three out of nine participants [33.3%], for each AE). The only AE that was Grade 3 or above was lymphopenia observed in three participants, some of whom had bone metastasis at baseline and/or had received multiple lines of therapy, including taxane and an investigational agent, prior to enrolment in the SECuRE study. There have been no overall renal toxicity or electrocardiogram (ECG) changes observed in these participants. In the combination enzalutamide arm, no new AEs (or worsening of AEs) related to ⁶⁷Cu-SAR-bisPSMA have been observed to date.

Trial participant with no detectable disease after 3 cycles of ⁶⁷Cu-SAR-bisPSMA

One of the participants in the Cohort Expansion was a 64-year-old man with bone metastases and baseline PSA of 5.4 ng/mL prior to entering the SECuRE study. Following his first cycle of ⁶⁷Cu-SAR-bisPSMA, this participant showed a dramatic 95.2% reduction in PSA. He went on to receive 2 more cycles of ⁶⁷Cu-SAR-bisPSMA and achieved undetectable PSA levels. In a follow-up bone scan and CT no metastatic disease was observed. This participant only exhibited mild (Grade 1) related AEs, most of which were gastrointestinal events, with no haematological or renal AEs observed. The participant reported having excellent quality of life following the treatment.

The interim data from this Phase II continues to confirm the favourable safety profile and promising efficacy seen in previous cohorts of the SECuRE trial^[1] and supports the continuation of the trial with the aim to progress to a registrational Phase III study.

Clarity's Executive Chairperson, Dr Alan Taylor, commented, "SAR-bisPSMA continues generating world-class data in both theranostic and diagnostic trials. The combination of the optimised dimer 'bis' structure with the benefits of copper isotopes, enabled by the proprietary sarcophagine technology, is proving to have created a product that is here to challenge the current treatment and diagnostic paradigms in radiopharmaceuticals.

"We have already seen a glimpse of the effects of ⁶⁷Cu-SAR-bisPSMA through our Dose Escalation cohorts with additional and similar data being generated in the Cohort Expansion phase, demonstrating once again excellent efficacy and safety results of ⁶⁷Cu-SAR-bisPSMA.

"All of the participants with evaluable data treated in the Phase II to date have shown declines in PSA, with the majority showing PSA decreases of more than 50% and mostly having only mild or moderate AEs. Most of these patients have been treated with more than 5 systemic treatment regiments and had bone metastasis prior to entering the SECuRE study. Although the number of participants with evaluable data to date is small, it is incredible to see yet another extraordinary case where a patient who had bone metastasis prior to entering the study achieved undetectable PSA following ⁶⁷Cu-SAR-bisPSMA treatment, with no disease observed by anatomical and molecular imaging at the last assessments. This participant only experienced mild, transient AEs, most being gastrointestinal, and has reported having excellent quality of life following the treatment.

"Importantly, the work we have undertaken during the Dose Escalation Phase is now continuing to provide a strong foundation for us as we look ahead at protocol development and dosing for our Phase III clinical trial and commercialisation. As the participant numbers continue to increase with the trial enrollment, we continue to see very promising responses over and over again, giving us more confidence about the future of this product and its potential for commercialisation in metastatic castration-resistant prostate cancer (mCRPC). With three Fast Track Designations for the SAR-bisPSMA product and positive interactions with the US Food and Drug Administration (FDA) to date, we are working towards bringing this agent to clinicians and their patients around the world through the entirety of the prostate cancer journey, from first diagnosis to late-stage disease. All of these indications, being imaging in pre-definitive therapy and biochemical recurrence, as well as therapy in mCRPC, are blockbuster markets individually for prostate-specific membrane antigen (PSMA) targeted products, with an estimated combined market value of approximately US$10-15 billion by 2030. We are committed to continuing the development of this product, aiming to bring improved diagnostic and treatment options for prostate cancer in various stages of their disease."

About the SECuRE trial

The SECuRE trial (NCT04868604)^[2] is a Phase I/IIa theranostic trial for identification and treatment of participants with PSMA-expressing mCRPC using ⁶⁴Cu/⁶⁷Cu-SAR-bisPSMA. ⁶⁴Cu-SAR-bisPSMA is used to visualise PSMA-expressing lesions and select candidates for subsequent ⁶⁷Cu-SAR-bisPSMA therapy. The trial is a multi-centre, single arm, dose escalation study with a cohort expansion involving approximately 54 participants in the US. The overall aim of the trial is to determine the safety and efficacy of ⁶⁷Cu-SAR-bisPSMA for the treatment of prostate cancer.

The SECuRE trial consists of the Dose Escalation (Phase I) and Cohort Expansion (Phase II) Phases. Based on the data from the Dose Escalation Phase, which demonstrated a favourable safety profile and efficacy of ⁶⁷Cu-SAR-bisPSMA, the SECuRE trial progressed to the Cohort Expansion (Phase II) at an 8 GBq dose level as per the SRC recommendation (up to 6 cycles per patient in total)^[3].

Cohort 2 of the Dose Escalation phase of the trial, where participants were dosed with 8 GBq of ⁶⁷Cu-SAR-bisPSMA, demonstrated a very low rate of related AEs while all three participants achieved PSA declines of 80% or more (PSA80)^[1]. The Dose Escalation Phase also showed high PSA response rates of the mCRPC in the pre-chemotherapy setting with a favourable safety profile: 92% of pre-chemotherapy participants (12/13) demonstrated PSA drops greater than 35%, PSA reductions greater than 50% were reached in 61.5% (8/13) of participants, and reductions of 80% or more were achieved in 46.2% (6/13) of participants^[1]. These results supported the progress of the trial to its Cohort Expansion Phase using 8 GBq multi-dose in participants who had not received chemotherapy in the mCRPC setting.

Recruitment is currently ongoing into the Cohort Expansion Phase which will include 24 participants. A subset of participants will be treated with the combination of 8 GBq of ⁶⁷Cu-SAR-bisPSMA with enzalutamide (androgen receptor pathway inhibitor [ARPI]), in line with the positive results from the Enza-p trial^[4] and previous discussions with and advice from key global medical experts in the field of prostate cancer, including the Company's Clinical Advisory Board members, Prof Louise Emmett and Prof Oliver Sartor, as well as the SRC.

About SAR-bisPSMA

SAR-bisPSMA derives its name from the word "bis", which reflects a novel approach of connecting two PSMA-targeting agents to Clarity's proprietary sarcophagine (SAR) technology that securely holds copper isotopes inside a cage-like structure, called a chelator. Unlike other commercially available chelators, the SAR technology prevents copper leakage into the body. SAR-bisPSMA is a Targeted Copper Theranostic (TCT) that can be used with isotopes of copper-64 (Cu-64 or ⁶⁴Cu) for imaging and copper-67 (Cu-67 or ⁶⁷Cu) for therapy.

⁶⁷Cu-SAR-bisPSMA and ⁶⁴Cu-SAR-bisPSMA are unregistered products. The safety and efficacy of ⁶⁷Cu-SAR-bisPSMA and ⁶⁴Cu-SAR-bisPSMA have not been assessed by health authorities such as the US FDA or the Therapeutic Goods Administration (TGA). There is no guarantee that these products will become commercially available.

About Prostate Cancer

Prostate cancer is the second most common cancer diagnosed in men globally and the fifth leading cause of cancer death in men worldwide^[5]. Prostate cancer is the second-leading causes of cancer death in American men. The American Cancer Institute estimates in 2025 there will be about 313,780 new cases of prostate cancer in the US and around 35,770 deaths from the disease^[6].

About Clarity Pharmaceuticals

Clarity is a clinical stage radiopharmaceutical company focused on the treatment of serious diseases. The Company is a leader in innovative radiopharmaceuticals, developing TCTs based on its SAR Technology Platform for the treatment of cancers.

www.claritypharmaceuticals.com

For more information, please contact: